Երկիր: Մալթա
Լեզու: անգլերեն
Աղբյուրը: Medicines Authority
calcitonin, salmon 100 iu/ml
Novartis Pharmaceuticals UK Limited
H05BA01
calcitonin, salmon
solution for injection
Authorised
2006-05-31
Miacalcic ® Ampoules READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TREATMENT WITH MIACALCIC AMPOULES Keep this leaflet. You may need to read it again This medicine has been prescribed only for you. Do not give it to anybody else or use it for any other illnesses. If you have further questions, please ask your doctor or pharmacist. IN THIS LEAFLET 1 What Miacalcic solution for injection or infusion is and what it is used for 2 What you need to know before you use Miacalcic solution for injection or infusion 3 How to take Miacalcic solution for injection or infusion 4 Possible side effects 5 How to store Miacalcic solution for injection or infusion 6 Contents of the pack and other information MIACALCIC 100 IU/ML SOLUTION FOR INJECTION OR INFUSION IN AMPOULES The ACTIVE SUBSTANCE is synthetic salmon calcitonin. The OTHER INGREDIENTS ARE acetic acid, sodium acetate trihydrate, sodium chloride and water for injections. MANUFACTURED BY: Novartis Pharma Stein AG Schaffhauserstrasse CH-4332 Stein Switzerland RELEASED ONTO THE MARKET BY: V.J. Salomone Pharma Ltd. 75, Simpson Street, Marsa, MRS 1606 Malta. MARKETING AUTHORISATION HOLDER Novartis Pharmaceuticals UK Ltd. Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, England 1 WHAT MIACALCIC SOLUTION FOR INJECTION OR INFUSION IS AND WHAT IT IS USED FOR Miacalcic solution for injection or infusion can be given for the following conditions: - Prevention of bone loss in patients who have suddenly become immobile. For example, patients who are bed-bound because of a fracture. - Paget’s disease of bone in patients who cannot take other treatments for this condition, for example patients with Կարդացեք ամբողջական փաստաթուղթը
Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT MIACALCIC AMPOULES 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active substance is synthetic salmon calcitonin (INN name Calcitonin). One millilitre contains 100 IU of synthetic salmon calcitonin. One International Unit (= IU) corresponds to about 0.2 micrograms of synthetic salmon calcitonin. For excipients see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Miacalcic is available as a solution for injection in ampoules (1 mL) containing 100 IU/mL 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures. For the treatment of Paget’s disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment. Treatment of hypercalcaemia of malignancy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Due to evidence of an increased risk of malignancies and long term calcitonin use (see section 4.4), the treatment duration in all indications should be limited to the shortest period of time possible and using the minimum effective dose. Salmon calcitonin may be administered at bedtime to reduce the incidence of nausea or vomiting which may occur, especially at the initiation of therapy. _PREVENTION OF ACUTE BONE LOSS DUE TO SUDDEN IMMOBILIZATION SUCH AS IN PATIENTS WITH RECENT _ _OSTEOPOROTIC FRACTURES:_ The recommended dosage is 100 I.U. daily or 50 I.U. twice daily administered subcutaneously or intramuscularly. The dose may be reduced to 50 Կարդացեք ամբողջական փաստաթուղթը